Cesar Sánchez1, Francisco Domínguez2, Héctor Galindo1, Mauricio Camus2, David Oddó3, Alejandra Villarroel3, Dravna Razmilic4, María Elena Navarro4, Alejandra Pérez-Sepúlveda1, Lidia Medina5, Valeska López5, Francisco Acevedo1. 1. Departamento de Hematología-Oncología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 2. Departamento de Cirugía Oncológica y Maxilofacial, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 3. Departamento de Anatomía-Patológica, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile. 4. Departamento de Radiología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Chile. 5. Centro de Cáncer Nuestra Señora de La Esperanza, Pontificia Universidad Católica de Chile, Santiago, Chile.
Abstract
BACKGROUND: HER2+ breast cancer (BC) subtype overexpresses the Human Epidermal growth factor Receptor type-2 (HER2) and is characterized by its aggressiveness and its high sensitivity to monoclonal antibody-based HER2-targeted therapies. AIM: To assess the prognosis and evaluate the impact of novel anti-HER2 therapies on advanced HER2+ BC patients treated at our institution over the last decades. MATERIAL AND METHODS: Analysis of the patient database at a cancer center of a university hospital. Information about the subtype of cancer was obtained in 2,149 of 2,724 patients in the database. Eighteen percent of the latter were HER2+. We analyzed data of 83 of these patients with advanced disease. RESULTS: Median overall survival (OS) was 24 months. For patients treated between 1997-2006 median OS was 17 months and for those treated in the period 2007-2017 median OS was 32 months (p = 0.09). CONCLUSIONS: A non-significant trend towards better survival in the last decade was observed. HER2+ BC overall survival has improved in our center. This can be probably attributed to the use of novel more effective anti-HER2 therapies.
BACKGROUND:HER2+ breast cancer (BC) subtype overexpresses the Human Epidermal growth factor Receptor type-2 (HER2) and is characterized by its aggressiveness and its high sensitivity to monoclonal antibody-based HER2-targeted therapies. AIM: To assess the prognosis and evaluate the impact of novel anti-HER2 therapies on advanced HER2+ BC patients treated at our institution over the last decades. MATERIAL AND METHODS: Analysis of the patient database at a cancer center of a university hospital. Information about the subtype of cancer was obtained in 2,149 of 2,724 patients in the database. Eighteen percent of the latter were HER2+. We analyzed data of 83 of these patients with advanced disease. RESULTS: Median overall survival (OS) was 24 months. For patients treated between 1997-2006 median OS was 17 months and for those treated in the period 2007-2017 median OS was 32 months (p = 0.09). CONCLUSIONS: A non-significant trend towards better survival in the last decade was observed. HER2+ BC overall survival has improved in our center. This can be probably attributed to the use of novel more effective anti-HER2 therapies.